Revolution Medicines announced a stunning survival benefit for its experimental drug, daraxonrasib, in a Phase 3 pancreatic cancer study this week. Patients with advanced pancreatic adenocarcinoma treated with the daily pill lived a median of 13.2 months, compared to just 6.7 months for those receiving standard chemotherapy.
This groundbreaking data positions Revolution Medicines to apply for Food and Drug Administration approval, although a timeline for submission remains unspecified. Given the compelling results, regulatory approval could be expedited, marking a significant milestone in the treatment landscape for pancreatic cancer.
In an interview with STAT, Paul Oberstein from NYU Langone’s Perlmutter Cancer Center, an investigator in the trial, emphasized the potential of daraxonrasib to transform treatment paradigms. The implications of this study could pave the way for improved outcomes in a disease historically characterized by poor prognosis.
Use the database as your supply chain compass →
